Antitrust regulators are investigating whether mid-sized biopharma acquisitions could suppress early-stage clinical innovation or delay secondary indication trials in rare diseases.
Clinical investigators are expanding CRISPR gene editing into children aged five to eleven, aiming to reactivate fetal hemoglobin before cumulative sickle cell vasculopathy becomes irreversible.
Recruiting cellular E3 ubiquitin ligases allows molecular glues and PROTACs to eliminate oncogenic transcription factors lacking classic small-molecule binding pockets.
Public market investors are rewarding Phase 2 clinical proof-of-concept in metabolic disease and ADCs while preclinical platform discovery engines face strict valuation discipline.
Regulators are requiring confirmatory Phase 3 trials to be actively enrolling before granting accelerated approval, eliminating years of post-market clinical uncertainty.
A major amendment to chemistry and manufacturing controls prompted a three-month FDA review extension, giving Pfizer additional runway in ATTR cardiomyopathy.
A dedicated radiopharmaceutical production complex in Indianapolis aims to secure domestic actinium-225 and lutetium-177 supplies as oncology demand surges.
CMS published maximum fair prices for the initial ten Part D blockbusters, forcing drug developers to re-evaluate small-molecule discovery timelines and indication stacking.
Targeted lipid nanoparticles reprogramming circulating T cells inside the body achieved complete metabolic responses, bypassing complex ex vivo manufacturing logistics.
Phase 3 vutrisiran data demonstrated a 28% reduction in mortality risk, setting up an upstream gene-silencing showdown against Pfizer's incumbent oral blockbuster tafamidis.
Venture syndicates are concentrating capital into $100M+ Series A and B rounds for clinical-stage assets, leaving early-stage discovery platforms to navigate lean seed environments.